Analyst
KeyBanc Capital Markets
Equibles does not estimate personal net worth.
Paul Knight is recorded as Analyst at KeyBanc Capital Markets. Paul Knight has spoken on 4 earnings calls across 4 companies, most recently for Harvard Bioscience Inc on August 11, 2026. Those appearances were for Harvard Bioscience Inc (HBIO), Mesa Laboratories Inc (MLAB), Lifecore Biomedical, Inc. De (LFCR) and Aptargroup, Inc. (ATR). The companies whose calls Paul Knight spoke on are classified in the Healthcare and Technology sectors.
“And with the China demand that we're seeing, could you talk a little bit about it specifically? Is it electroporation products? Is it the mesh MEA? And then, how do you control your China sales?”
“The question I think a lot of people would have is, you know, this has historically been a company focused on some merger and acquisition activity. What do you think are some of the key portions of the business that are easiest to build upon?”
“I know there was some press release regarding the preferred. Where are you with that particular instrument?”
“As I look at the quarter, you know, the gross margin was not the driver of expansion in Q2. It was the off margin line with a big drop at SG&A. Going forward, I think it's implying margin expansion.”
KeyBanc Capital Markets
Analyst
Transcript header (unverified)
Medical Instruments & Supplies · Healthcare
Scientific & Technical Instruments · Technology
Drug Manufacturers - Specialty & Generic · Healthcare
ATR
Medical Instruments & Supplies · Healthcare
